Search bioRxiv⌕ Search

Biology subjects

Allen, L.-A. H.

Publications and source records attributed to Allen, L.-A. H..

2 recordsLinked to original sources

Sphingosine kinase 2 suppresses neutrophil responses to promote viral persistence while attenuating immune pathology

Chronic virus infections often suppress immune cell functions which helps in restricting immune pathology but leads to viral persistence. However, the underlying mechanisms are incompletely understood. We recently found that sphingosine kinase 2 (SphK2)-deficient (Sphk2-/-) mice succumbed to lymphocytic choriomeningitis virus (LCMV) infection due to immune pathology. In addition to heightened T cell immunity, a notable increase of neutrophils was observed in LCMV-infected Sphk2-/- mice. Depletion of neutrophils increased the viability of virus-infected Sphk2-/- mice, supporting a role of SphK2-deficient neutrophils in viral immune pathogenesis. Further, SphK2-deficient neutrophils expressed lower levels of the immune suppressive marker CD244 during infection. Importantly, adoptively transferred SphK2-deficient neutrophils demonstrated intrinsic regulation of CD244 and improved virus-specific T cell responses, resulting in diminished viral burden. Transcriptomic analysis revealed increased expression of pro-inflammatory and antiviral genes in SphK2-deficient neutrophils. These results indicate that SphK2 promotes suppressive neutrophil responses and regulates neutrophil-associated immune pathology during a persistent infection. Our findings may help design new immune therapeutics to control chronic viral diseases. SignificanceNeutrophils are the sentinels of the innate immune system; they can reshape innate and adaptive immune responses. During chronic illnesses, such as persistent viral infections, neutrophils can suppress the host immune response and help in disease progression. Here, we demonstrate regulation of neutrophil expansion and functions by sphingosine kinase 2 (SphK2) during LCMV infection. SphK2-deficient neutrophils express a reduced level of inhibitory receptor CD244, exert immune stimulatory effects on T cells, and promote virus clearance. Further, transcriptomic analysis reveals that SphK2 deficiency leads to the development of proinflammatory neutrophils. Our study identifies SphK2, a host factor, as being critical for neutrophil suppression that regulates dysfunctional T cell response and virus persistence.

immunology↗

DUSP11 is an intracellular innate immune checkpoint in lung adenocarcinoma

The discovery of immune checkpoints and the rapid growth of immuno-oncology (IO) have sparked tremendous efforts to utilize the immune system to treat a wide range of cancer types/subtypes. While the major focus of IO over the past decades has been to manipulate the adaptive immune system, recent attention has been given to manipulating the innate immune system to treat cancer and/or to enhance adaptive responses. In this work we detail the intracellular protein, Dual Specificity Phosphatase 11 (DUSP11), as an innate immune checkpoint (iIC) in Non-Small Cell Lung Cancer (NSCLC) adenocarcinoma (LUAD). Expression of this atypical phosphatase is correlated with patient survival for multiple cancer types, and we show here that its activity is important for the viability of lung cancer cells in vitro. Specifically, we demonstrate that DUSP11 knockdown in LUAD cells induces apoptosis and an innate immune response capable of activating other cells in vitro, and we provide evidence that these phenotypes are primarily mediated by the pattern recognition receptor, retinoic acid inducible gene I (RIG-I). Finally, we show that expression of DUSP11 is important for tumor engraftment and growth of human LUAD in mice. Overall, these data are the first to establish DUSP11 as an immunosuppressive, pro-neoplastic, and potentially targetable protein in LUAD. In addition, our data suggests that the anti-cancer mechanisms induced by diminishing the activity of DUSP11 are likely to be generalizable to other cancer types such as breast cancer, warranting future investigation and therapeutic development.

cancer biology↗